focus -WSS

focus

author：focus 2025-08-23 08:56:52 - browse：278

Boston Scientific headquarters -- Health coverage from STAT — Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： MD Anderson's Padmanee Sharma responds to research credit suit

Wikipedia

WSS

In 'major milestone,' FDA approves first cell therapy for solid tumors

Menendez indictment could see pharma lose a key ally

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Surprise medical billing ban raises prices elsewhere

Covid vaccines: Private market messier than government rollout

As AI regulations shape up, health tech startups beg for clarity

hotspot

focus

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Address the ethical violations that led to 'Three Identical Strangers'

Supreme Court strikes down use of affirmative action

Medicare Advantage enrollment grows 7.1% to 33.4 million people

In age of alternative facts, a scholarly course on calling out crap

MD Anderson's Padmanee Sharma responds to research credit suit

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA seeks to regulate lab

What does generative AI mean for health care? We asked experts

Ukraine seeks to reclaim its role as a hub for clinical trials

leisure time

Mindstrong's demise and the future of mental health care

After a drawn out lobbying fight, ARPA

Congress may force more Covid

Weight loss drugs aren’t covered by Obamacare. That may change

Biogen shutters digital health group, ends Apple study, in cost cutting move

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

hotspot

Wikipedia

explore

hotspot